• The Allergy Therapeutics portfolio has a good position in the market due to the innovative approach to product design that focuses on short or ultra-short course treatment
  • Short & ultra short course treatments aim to ensure better patient adherence and successful outcomes
  • We aim to get the MATA MPL product portfolio to the US market, pending successful trials, which is a huge opportunity in a brand new market
  • The US market has an allergic rhinitis market for severe patients of about $2bn and currently there are no approved SCIT products in the market
  • The Allergy Therapeutics business has already developed a high quality and successful platform for allergic rhinitis and is using the skills and insights from this in further developments in adjuvants, subcutaneous treatments and immunology to develop new platforms for food allergies and diseases outside of the allergy space, including: melanoma, asthma, atopic dermatitis and psoriasis